Physician profile
Aaron Broman
NPI 1386961076
$1,358.92
in general payments reported to CMS, 2019-2025
14 companies · $175 in 2025
The $175 reported for 2025 was more than what 78% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.15 · 2022: $475 · 2023: $455 · 2024: $229 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $840 · Education: $19.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $840.09 |
| Education | $19.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $711.40 | 2022-2025 | Entyvio, Gattex |
| Abbvie INC. | $137.25 | 2022-2023 | Mavyret |
| Nestle Healthcare Nutrition INC. | $100.53 | 2022 | |
| Merck Sharp & Dohme LLC | $67.76 | 2023 | Dificid |
| Janssen Biotech, INC. | $61.01 | 2023-2024 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.23 | 2022-2025 | Xifaxan, Plenvu |
| Redhill Biopharma INC. | $42.72 | 2022 | |
| Celltrion USA INC. | $40.18 | 2023-2025 | Vegzelma, Yuflyma |
| Fresenius Kabi USA, LLC | $31.38 | 2023 | |
| Ardelyx, INC. | $29.51 | 2023 | Ibsrela |
| Trevena, INC. | $24.15 | 2021 | |
| Daiichi Sankyo INC. | $23.30 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.99 | 2022 | |
| Fisher & Paykel Healthcare INC | $14.51 | 2024 | Fisher & Paykel Healthcare |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Broman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.